A Comparative Study of Mefloquine and S-P as Prophylaxis Against Malaria in Pregnant HIV + Patients

ORIYOMI OMOTOYOSI AKINYOTU142 enrolled

Overview

Randomized controlled single blind prospective comparative study.

This study is intended to be a randomized controlled single blind prospective comparative study conducted to compare the efficacy of three, monthly doses of sulphadoxine-pyrimethamine as intermittent preventive therapy with Mefloquine as-intermittent preventive therapy in HIV-infected pregnant women.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

142

Conditions

Malaria in Pregnant HIV + Patients

Interventions

MefloquineDRUG

Tabs Mefloquine 250mg

Sulphadoxine-PyrimethamineDRUG

Sulphadoxine 500mg , Pyrimethamine 25mg

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Pregnant HIV positive patients * Gestational age 16 weeks and above * No history of use of Mefloquine or Sulphadoxine * Pyrimethamine four weeks prior to recruitment. Exclusion Criteria: * Anaemia packed cell volume less than 30% * Pre -existing medical conditions- Diabetes Mellitus, -Hypertension * Allergy to Sulphadoxine- Pyrimethamine or Mefloquine * Non-consenting patients * Multiple gestation * Known psychiatric illness * Known seizure disorder * History of severe renal or hepatic disease

Locations (1)

University College Hospital

Ibadan, Oyo State, Nigeria

Outcomes

Primary Outcomes

Level of malaria parasitemia in HIV positive women at delivery after administration of Mefloquine or sulphadoxine-pyrimethamine as prophylaxis for malaria in pregnancy

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.